Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The stud...
BOT/BAL Demonstrates Broad and Durable Activity in Advanced Sarcoma Population
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today...
B. Riley Securities analyst Yuan Zhi maintains Agenus (NASDAQ:AGEN) with a Buy and lowers the price target from $42 to $18.
Agenus (NASDAQ:AGEN) reported quarterly losses of $(2.52) per share which missed the analyst consensus estimate of $(1.07) by 1...
Antibody, Is Effective Against Tumors Poorly Responsive to Conventional Immunotherapy," highlights several key findings:Dem...
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AG...
Jefferies analyst Biren Amin downgrades Agenus (NASDAQ:AGEN) from Buy to Hold and raises the price target from $3 to $7.
Agenus faces a setback as the FDA advises against accelerated approval for its immunotherapy combination, botensilimab and bals...
